Medtronic Raises Fiscal 2025 Guidance
By Brian Nelson, CFA Medical device giant Medtronic (MDT) recently reported fiscal first quarter fiscal 2025 results that came in better than expectations. Adjusted revenue was $8 billion in the quarter led by 5.3% organic growth. Adjusted diluted earnings per share was $1.23, up 2.5% and 7.5% in constant currency. In the quarter, its Cardiovascular segment experienced 6.9% organic growth, its Neuroscience segment experienced 5.3% organic growth, its Diabetes segment experienced 12.6% organic growth, while its Medical Surgical segment experienced 1% organic growth. Year-to-date, operating cash flow was $1 billion, while free cash flow was $0.5 billion. ESG Matters Image Source: Medtronic Medtronic has a number of long-term sustainability objectives that are worth mentioning. It expects to reduce greenhouse gas … Read more